What is ascertained in the therapy of axial spondyloarthritis? (Q46057173)

19 December 2017

title

What is ascertained in the therapy of axial spondyloarthritis? (English)

1 reference

19 December 2017

author name string

J Braun

1

1 reference

19 December 2017

X Baraliakos

2

1 reference

19 December 2017

F Heldmann

3

1 reference

19 December 2017

U Kiltz

4

1 reference

19 December 2017

language of work or name

German

0 references

publication date

1 December 2013

1 reference

19 December 2017

published in

Die Innere Medizin

1 reference

19 December 2017

volume

54

1 reference

19 December 2017

issue

12

1 reference

19 December 2017

page(s)

1450-1458

1 reference

19 December 2017

cites work

Ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Genetics of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00108-013-3331-7

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial.

21 January 2018

1 reference

12 December 2020

The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis

1 reference

12 December 2020

Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study

1 reference

12 December 2020

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

1 reference

12 December 2020

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

1 reference

12 December 2020

[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area]

1 reference

12 December 2020

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

1 reference

12 December 2020

Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group

1 reference

12 December 2020

[ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area]

1 reference

12 December 2020

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial

1 reference

12 December 2020

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab

1 reference

12 December 2020

10.1007/S00108-013-3331-7

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017